SMC Corp Stock Surges as Palliser Capital Pushes for Major Share Buyback 
Microsoft Commits $18 Billion to Expand AI and Cloud Infrastructure in Australia 
European Car Sales Surge in March as EV and Hybrid Demand Accelerates 
DeepSeek Launches V4 AI Models with Enhanced Reasoning and 1M Token Context Window 
Mercedes-Benz Faces Rising Competition in China but Rejects Price War Strategy 
Strait of Hormuz Shipping Crisis Deepens as Traffic Plunges Amid Iran-U.S. Tensions 
Chinese Chip Stocks Surge on AI Boom and Domestic Tech Push 
U.S. Demand for Alternative Satellite Providers Remains Strong Amid SpaceX Regulatory Push 
Organon Stock Surges After Reports of $13 Billion Buyout Bid by Sun Pharma 
DeepSeek Slashes AI Model Pricing to Boost Adoption and Challenge Global Rivals 
Why Global Web3 Projects Can't Afford to Skip South Korea: TokenPost Unveils Data-Driven Entry Solutions 
U.S. Sanctions Target Chinese Refinery Over Iranian Oil Purchases 
Taiwan Court Fines Tokyo Electron Unit $4.78M in Major TSMC Trade Secrets Case 
U.S. Raises Alarm Over Chinese AI Firms’ Alleged IP Theft Through Model Distillation 
Brazil Pension Fund Crackdown After Banco Master Collapse Raises Investment Concerns 
Toyota Global Vehicle Sales Decline in March Amid RAV4 Transition and Middle East Slowdown 
RA’ANANA, Israel, May 11, 2017 -- UroGen Pharma Ltd. (NASDAQ:URGN), a clinical stage biopharmaceutical company developing advanced non-surgical treatments to address unmet needs in the field of urology, with a focus on uro-oncology, announced today that the Company has been selected for an oral podium presentation and a poster presentation at the upcoming American Urology Association 2017 Annual Meeting in Boston, Massachusetts from May 12 to May 16, 2017.
The oral podium and poster presentations are related to UroGen Pharma’s clinical stage uro-oncology product candidates, as detailed below:
Oral podium presentation: PD19-10: The Chemoablative Effect of VesiGel Instillation in Patients with NMIBC – Response Rate and One-Year Durability
Presenting Author: Andrew Lenis, MD MS, Department of Urology, David Geffen School of Medicine at UCLA, Los Angeles, California
Session: Bladder Cancer: Non-Invasive II on Saturday, May 13 from 8:30 am EDT to 8:40 am EDT
Poster presentation based on abstract title: MP98-05: Checkpoint Inhibition with Systemic Anti-Programmed Cell Death Ligand-1 and Intravesical TMX-101 (Vesimune) Decrease Tumor Burden in a Mouse Model of Urothelial Carcinoma
Presenting Author: Andrew T. Lenis MD MS, Department of Urology, David Geffen School of Medicine at UCLA, Los Angeles, California
Session: Bladder Cancer: Basic Research & Pathophysiology on Tuesday, May 16 from 9:30 am EDT to 11:30 am EDT
About UroGen Pharma Ltd.
UroGen Pharma is a clinical stage biopharmaceutical company developing advanced non-surgical treatments to address unmet needs in the field of urology, with a focus on uro-oncology. The Company has developed RTGel, a proprietary sustained release, hydrogel-based formulation for potentially improving the efficacy and safety profiles of existing drugs. UroGen Pharma's sustained release technology is designed to enable longer exposure of the urinary tract tissue to medications, making local therapy a potentially more effective treatment option. UroGen Pharma's lead product candidates, MitoGel and VesiGel, are designed to potentially remove tumors by non-surgical means and to treat several forms of non-muscle invasive urothelial cancer, including low-grade UTUC and bladder cancer. UroGen Pharma is headquartered in Israel and also maintains a corporate office in New York City.
CONTACT: Gary Titus, UroGen Pharma Ltd. 689 Fifth Avenue, 14th Floor New York, NY 10022 [email protected] 646-768-9531 Stephanie Carrington, ICR, Inc. 685 Third Avenue, 2nd Floor New York, NY 10017 [email protected] 646-277-1282
